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Background: Therapies based on mesenchymal stem cells (MSC) have been shown to have potential benefit in
several clinical studies. We have shown that, using a medium-based approach, MSC can be induced to secrete
elevated levels of neurotropic factors, which have been shown to have protective effects in animal models of
neurodegenerative diseases.
These cells, designated MSC-NTF cells (Neurotrophic factor-secreting MSC, also known as NurOwn™) derived from
the patient's own bone marrow, have been recently used for Phase I/II and Phase IIa clinical studies in patients with
Amyotrophic Lateral Sclerosis (ALS). In these studies, ALS patients were subjected to a single administration of
autologous MSC-NTF cells. The data from these studies indicate that the single administration of MSC-NTF cells is
safe and well tolerated.
In a recently published case report, it was shown that repeated MSC-NTF injections in an ALS patient treated on a
compassionate basis were safe and well tolerated [Muscle Nerve 49:455-457, 2014].
Methods: In the current study we studied the toxicity and tolerability of three consecutive intramuscular injections
(IM) of cryopreserved human MSC-NTF cells in C57BL/B6 mice to investigate the effect of repeated administration
of these cells.
Results: Monitoring of clinical signs and immune reactions showed that repeated injections of the cells did not
lead to any serious adverse events. Pathology, histology and blood biochemistry parameters tested were found to
be within normal ranges with no sign of tumor formation.
Conclusions: Based on these results we conclude that repeated injections of human MSC-NTF are well tolerated in
mice. The results of this study suggest that if the outcomes of additional clinical studies point to the need for
repeated treatments, such option can be considered safe.
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We have developed a medium-based protocol for inducing
the differentiation of bone marrow-derived multi-potent
mesenchymal stromal cells (MSCs) into neurotrophic
factor-secreting cells (MSC-NTF cells). These MSC-NTF
cells have been developed into a novel cell therapy which
aims to target the affected motor neurons via delivery of
Neurotrophic Factors (NTF) directly to the site of tissue
damage in Amyotrophic Lateral Sclerosis (ALS) patients.* Correspondence: ygothelf@brainstorm-cell.com
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in any medium, provided the original work is pIn this cell therapy approach, the patients’ bone marrow
derived MSCs are propagated ex-vivo and induced to
secrete elevated levels of NTF such as Glial Cell Line
Derived Neurotrophic Factor (GDNF) and Brain-derived
neurotrophic factor (BDNF), Vascular Endothelial Growth
factor (VEGF) and Hepatocyte Growth factor (HGF).
These NTF are delivered to the cell body in the spinal
cord via intrathecal (IT) administration, and/or to the
motor end plates via intramuscular (IM) administration.
In-vitro studies demonstrated that the cell-conditioned
medium protects neurons against neurotoxic insults, and
in-vivo studies have shown that NTF-secreting cells havean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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ative diseases such as Parkinson’s disease, multiple sclerosis,
Huntington’s disease and sciatic nerve injury where the
transplanted animals showed marked improvements [1-5].
Several models of motor neuron disorders have been
used for studying the administration of NTF and investi-
gating the regeneration of axons and functional recovery
[6-8]. Although some indications of restoration and re-
covery of the motor functions were shown, clinical trials
of systemic or IT administration of recombinant NTF to
patients with motor neuron disorders did not show sig-
nificant efficacy. It was suggested that this may be the
results of NTF short half-life, poor delivery and low con-
centrations at target sites [9,10]. The use of cellular
transplants to deliver NTF, either through their normal
release from the transplanted cells or after in-vitro ma-
nipulations of cells for the overexpression of certain
NTF, could provide improved sustained delivery.
In fact, in recent studies, human MSCs genetically engi-
neered to secrete GDNF and VEGF and transplanted into a
rat model of ALS, were shown to significantly increase the
number of neuromuscular connections and motor neuron
cell bodies in the spinal cord at mid stages of the disease, to
delay disease progression and increase lifespan [7,8].
One of the main issues concerning cell mediated treat-
ments, especially in chronic diseases, is cell survival. In
our previous study using MSC-NTF cells [2] we found,
as in other reports [11,12] that cell survival was limited
to the range of weeks, although the effect was main-
tained. Since there appears to be no direct correlation
between MSC engraftment and treatment response it is
suggested that MSCs mediate their function through a
“hit and run” mechanism [13].
Nevertheless since the effect of MSC-NTF appears to be
transient in patients [14], repeated administrations may be
needed to increase the beneficial effect of MSC-NTF cells.
Since the cells are autologous and derived from the pa-
tients’ own bone marrow, we developed a cryopreserva-
tion process that will allow banking of patients’ cells for
repeated use, thus avoiding the need for repeated bone
marrow aspiration procedures for harvesting of fresh cells.
The present study was aimed to evaluate the overall safety
and tolerability of repeated administrations of cryopre-
served human MSC-NTF cells in mice. In order to address
the possible complications following such treatment, we
designed a study to evaluate the applicability and safety of
repeated IM injections of MSC-NTF cells in mice. Our
data indicated that the mice tolerated the treatment well
and that the immune response was minimal.
Methods
Preparation and characterization of MSC-NTF cells
Human MSCs were isolated from bone marrow mono-
nuclear cells derived from healthy donors (Lonza). TheMSCs were expanded and induced to differentiate into
MSC-NTF cells using a medium based approach in which
cells were incubated for 72 hours in medium containing
1 mM dibutyryl cyclic AMP (cAMP), 20 ng/ml human Basic
Fibroblast Growth Factor (hbFGF), 5 ng/ml human platelet
derived growth factor (PDGF-AA), and 50 ng/ml human
Heregulin β1. MSC-NTF cells deriving from fresh MSC
were used for transplantation of the first group of mice.
For all successive transplantations MSC were cryopre-
served in 10% Dimethyl sulfoxide (DMSO) in growth
medium using a controlled rate freezer (Kryo 360–3.3,
Planer Plc UK). After thawing, the MSC were expanded
and induced to differentiate into MSC-NTF cells.
MSC and MSC-NTF cells are characterized by pheno-
typic analyses of cell surface antigens by flow cytometry.
As recommended by the International Society for Cellular
Therapy (ISCT) [15], human MSC should be character-
ized by expression of CD105, CD73 and CD90 surface
markers. To confirm the purity of the cell population and
to exclude the presence of hematopoietic cell contamin-
ation, these cells should lack expression of CD3, CD14,
CD19, CD34, CD45, and HLA-DR as determined by flow
cytometry. MSC-NTF cells are also tested for secretion of
neurotrophic factors into the culture supernatant by an
ELISA assay.
MSC-NTF cells were transplanted at a concentration
of 1 × 106 cells/100 μl in RPMI 1640 medium. Cells were
subjected to a gentle short manual mixing prior to each
withdrawal of cell suspension into a syringe.
Mice
In this study we used a total of 20 Male and 20 Female
C57BL/6JOlaHsd (Harlan Israel) mice, nine to ten weeks
of age. Mice were allowed free access to drinking water,
supplied to each cage via polyethylene bottles with stain-
less steel sipper tubes. The water was filtered (0.1-micron
filter), chlorinated, and acidified. During the acclimation
period and throughout the entire study duration, animals
were housed within a limited access rodent facility and
kept in groups of maximum five animals in polypropylene
cages (36.5 × 20.7 × 14.0 cm) that were fitted with solid
bottoms and filled with wood shavings as bedding material
(7093 Harlan Teklad Shredded Aspen). The mice were
allowed a six-day acclimation period to facility conditions
(20°C–24°C, 30%–70% relative humidity, and a twelve-
hour light/dark cycle) prior to inclusion in the study. Ani-
mal care and administration of MSC-NTF cells were con-
ducted at a GLP-certified site (Harlan Biotech Israel Ltd.,
Rehovot, Israel), and approved by the National Council for
Animal Experimentation.
Study design
To assess the potential toxic effects of the MSC-NTF cells,
the mice received either single or repeated IM injections
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5 male and 5 female mice was treated with a single IM in-
jection at a single dose. The second group (#2) of 5 male
and 5 female mice was injected with 2 successive IM injec-
tions with a 4 week interval, and the third group (#3) of 5
male and 5 female mice was injected with 3 successive IM
injections at 4 week intervals. An additional group (#4),
was injected with 3 successive IM injections at 4 week in-
tervals of RPMI 1640 medium, and served as the vehicle
control group. The animals were injected in both right
and left lateral thigh muscles via a 25G needle attached
to a 1 ml syringe. The MSC-NTF cells, 1 × 106 cells/ani-
mal, were injected at the constant dose volume of
100 μl/animal/dosing session, 50 μl/site. The vehicle
control group was subjected to identical experimental
conditions (Table 1).
We selected IM injections as the route of administra-
tion in this study, since it represents one of the routes
used in our clinical studies. The cell dose used in this
study is 50-fold the currently used clinical dose.
We have previously shown that repeated transplantation
was safe in compassionate use patients re-injected with
MSC-NTF after several months [14]. However, since the
positive clinical effect of the treatment was sustained for
only about 2–3 months, we sought to explore the possibil-
ity of administering repeat injections at shorter intervals.
Therefore, this study was aimed to confirm that re-
treatments at 4-week intervals could be safely tolerated,
while also taking into consideration a minimal recovery
time from any possible inflammation that may have
been caused in the mice by the previous injection.
Examinations and observations
Clinical examination
Individual clinical examinations were carried out immedi-
ately post-dosing, and up to the first 30 minutes, and at
least twice more during the first 2 hours of each dosing
session. Observations included changes in skin, fur, eyes,
mucous membranes, occurrence of secretions and excre-
tions (e.g. diarrhea) and autonomic activity (e.g. lacrima-
tion, salivation, piloerection, unusual respiratory pattern).
Changes in gait, posture and response to handling, as
well as the presence of bizarre behavior, tremors, con-
vulsions, sleep & coma were also followed and recorded.
Thereafter and through the entire observation period,Table 1 Experimental study design
Group no. No. of animals per group Test material
1 10 (5 males and 5 females) MSC-NTF cells
2 10 (5 males and 5 females) MSC-NTF cells
3 10 (5 males and 5 females) MSC-NTF cells
4 10 (5 males and 5 females) Vehicle Controlcage side clinical examinations were carried out and re-
corded once daily.
Body weight
Individual body weights were determined at randomization/
animal receipt procedure, shortly before each adminis-
tration of cells or vehicle control (dosing day), and there-
after twice weekly, and prior to the respective scheduled
termination.
Cytokine profile assay
Blood samples of approximately 10% of the total blood
volume of each animal were collected. Whole blood was
individually collected by retro-orbital sinus bleeding under
light CO2 anesthesia. Blood samples were taken at 2, 4
and 24 hours post dosing; at 2 hours post the second in-
jection, and at 4 hours post the third injection.
Cytokine profile assay was performed using BMS820FF
Mouse Th1/Th2 10plex Ready-to-Use kit for FlowCytomix
Multiplex, single well per serum sample for the detection
of the following cytokines: GM-CSF, IFN-γ, IL-1α, IL-2,
IL-4, IL-5, IL-6, IL-10, IL-17 and TNF-α.
Food consumption
Measurements of food consumption were initially carried
out during the acclimation period (prior to the first dosing
session), followed by weekly measurements throughout
the entire observation period. The last food consumption
measurement was carried out prior to the respective
scheduled termination.
Clinical pathology
Hematology and Biochemistry parameters were mea-
sured in all animals prior to their respective scheduled
termination. Blood samples (approximately 100 μl whole
blood collected in EDTA-coated tubes for hematology,
and approximately 180 μl serum collected in non-coated
tubes for biochemistry) were obtained by retro-orbital
sinus bleeding under light CO2 anesthesia. Blood sam-
ples were analyzed at the American Medical Laborator-
ies (Israel) Ltd. The standard biochemistry parameters
were tested using ROCHE-HITACHI/MODULAR P-800
and the hematology standard parameters were analyzed
by the Sysmex K × 21 system.Treatment
Dose (cells/animal) Frequency and route Study period
1 × 106 1 × IM Injection 4 weeks
1 × 106 2 × IM Injections 8 weeks
1 × 106 3 × IM Injections 12 weeks
0 3 × IM Injections 12 weeks
Table 2 Neurotrophic factor secretion
MSC MSC-NTF Fold induction
BDNF (pg/106 cells) 827 ± 128 1640 ± 125 1.98
GDNF (pg/106 cells) 161 ± 10 746 ± 68 4.6
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All animals were subjected to a fully detailed necropsy and
gross pathological examination following their respective
scheduled terminations. The examination included the ex-
ternal body surface, all orifices, cranial, thoracic and ab-
dominal cavities and their contents and any abnormality or
gross pathological changes observed in tissues and/or or-
gans. The following organs/tissues were collected and fixed
in 10% neutral buffered formalin (approximately 4% for-
maldehyde solution) and analyzed by Patho-Lab Diagnos-
tics Ltd.: heart, kidneys, liver, lungs, spleen, brain, inguinal,
lymph nodes injection sites (thigh muscle) and thymus.
Histopathological examination: tissues were trimmed,
embedded in paraffin, sectioned at approximately 5 mi-
crons thickness and stained with Hematoxylin & Eosin
(H&E). The injection site (right and left thigh muscula-
ture) was trimmed in the middle and about 2 mm prox-
imal and distal to the middle section. The histological
processing examinations were carried out by Dr. Abraham
Nyska, Israel.
Data evaluation
Statistical analysis of the following quantitative parameters
was confined to a comparison between results obtained for
animals that received three repeated IM injections of the
MSC-NTF cells and the animals that received the vehicle
control. The parameters that were compared were: clinical
pathology, organ weight, organ weight to body weight ra-
tio, body weight and percentage change in body weight.
Analyses were performed by the following methods in
order to determine significance of treatment effects: Soft-
ware: GraphPad Instat® - Version 3.02 (Statistical Method:
1-Way ANOVA; Unpaired T Test), Microsoft® Excel 2000.
Results
MSC and MSC-NTF cells characterization
MSC before differentiation were found to express > 95%
CD105, CD73 and CD90 surface markers, and to lack
expression of CD3, CD14, CD19, CD34, CD45, and
HLA-DR (<2%), as determined by flow cytometry. After
differentiation, MSC-NTF cells had the same phenotype
as MSC with the exception of CD105, which was
expressed on about 77% of the cells at the end of differ-
entiation. CD44, another characteristic marker of MSC,
was also found to be expressed on > 95% of both the
MSC and MSC-NTF cells.
BDNF and GDNF specific productivity of MSC-NTF
cells was also shown to be secreted about two and five
times higher, respectively, as compared to MSC cells of
the same donor (Table 2).
Clinical observation
No mortality as a result of treatment occurred in any of
the animals prior to the scheduled study termination.No clinical changes were noted in any of the MSC-NTF
treated animals, nor in any of the vehicle control-treated
animals throughout the entire study period.
Body weight
Body weight gain was noted in all animals at all termin-
ation time points (i.e. 28, 56 and 84 days post treatment
commencement). Mean body weight and percentage
change in body weight of groups treated with either a
single or repeated injections of the cells were found to
be similar to those of the Vehicle Control-treated group
(Table 2).
Organ weights
There was no statistically significant difference in the
mean organ weight to body weight ratio between the 3×
MSC-NTF treated group (Group No. 3) vs. the Vehicle
Control treated group (Group No. 4, Table 3).
Food consumption
Mean group food consumption values (gram/animal/
group) throughout all measuring sessions were within
the expected range for mice and there were no signifi-
cant differences between the various MSC-NTF cells-
treated and the Vehicle Control group.
Cytokine profile assay
The ELISA assay was chosen for cytokine profiling of
the serum samples in order to detect the levels of the ac-
tual proteins secreted.
Mean group cytokines secretion levels of groups
treated with either a single or repeated injections of the
MSC-NTF cells were comparable to those of the Vehicle
Control treated group. Although mean group values of
IFN-γ, IL-6 and TNF-α of groups treated with repeated
IM injections of the MSC-NTF cells were found to be
slightly higher than those of the Vehicle Control treated
group, those differences were quite small when com-
pared to results obtained using the immunostimulatory
compound LPS. The latter induced a biological response
in which secretion levels of the cytokines were elevated
by 4–5 times, and correlated to clinical changes (Harlan
Biotech Israel, Historical Data – Reference Controls, not
shown, Figure 1).
A significant difference in secretion of some of the cyto-
kines was identified: IL-1α increased in females vs vehicle
control group (p < 0.05) after the first injection, IL-6 in-
creased in both males and females after the second
Table 3 Body weight and selected organ weights of male and female C57BL/6 J mice following single or repeated
injections of MSC-NTF cells or the vehicle control
Treatment
4-week study 8-week study 12-week study
Parameter MSC-NTF cells single injection MSC-NTF cells 2 injections MSC-NTF cells 3 injections Vehicle 3 injections
Males
Terminal body weight (g) 26.2 (0.73) 27.4 (1.21) 30.3 (1.63) 33.6 (2.78)
Organ weight (g)
Brain 0.463 (0.012) 0.447 (0.015) 0.468 (0.018) 0.454 (0.03)
Liver 1.437 (0.12) 1.431 (0.114) 1.515 (0.239) 1.828 (0.214)
Lungs 0.188 (0.044) 0.205 (0.022) 0.219 (0.036) 0.205 (0.036)
Heart 0.141 (0.01) 0.154 (0.009) 0.178 (0.041) 0.175 (0.013)
Spleen 0.068 (0.019) 0.08 (0.019) 0.093 (0.019) 0.094 (0.022)
Organ weight to body weight ratio (mg organ weight/g body wt)
Brain 17.69 (0.85) 16.29 (0.52) 15.45 (0.98) 13.62 (1.7)
Liver 54.77 (3.66) 52.15 (3.44) 49.88 (6.85) 54.38 (1.99)
Lungs 7.16 (1.51) 7.48 (0.94) 7.24 (1.34) 6.16 (1.28)
Heart 5.39 (0.36) 5.64 (0.42) 5.86 (1.22) 5.23 (0.43)
Spleen 2.58 (0.67) 2.95 (0.79) 3.06 (0.6) 2.84 (0.82)
Females
Terminal body weight (g) 21.9 (1.07) 21.3 (0.90) 23.5 (1.69) 22.7 (0.78)
Organ weight (g)
Brain 0.443 (0.016) 0.444 (0.026) 0.474 (0.008) 0.462 (0.017)
Liver 1.078 (0.1) 1.051 (0.071) 1.166 (0.124) 1.080 (0.09)
Lungs 0.195 (0.035) 0.167 (0.02) 0.182 (0.034) 0.194 (0.021)
Heart 0.124 (0.012) 0.144 (0.008) 0.147* (0.01) 0.131 (0.011)
Spleen 0.088 (0.013) 0.076 (0.006) 0.112 (0.039) 0.097 (0.024)
Organ weight to body weight ratio (mg organ weight/g body wt)
Brain 20.19 (0.38) 20.85 (1.88) 20.23 (1.33) 20.36 (0.44)
Liver 49.05 (2.19) 49.24 (2.09) 49.56 (3.72) 47.52 (2.77)
Lungs 8.84 (1.39) 7.84 (1.0) 7.72 (1.24) 8.56 (0.92)
Heart 5.67 (0.37) 6.73 (0.42) 6.28 (0.35) 5.78 (0.55)
Spleen 4.02 (0.38) 3.55 (0.25) 4.82 (1.88) 4.28 (0.94)
Note: Values are mean (SD).
*Indicates statistical significance at p ≤ 0.05.
Gothelf et al. Clinical and Translational Medicine 2014, 3:21 Page 5 of 11
http://www.clintransmed.com/content/3/1/21injection (p < 0.001), IL-5 and IFN-γ increased in males
(p < 0.05 and p < 0.01 respectively) and IL-6 was found
to be increased at statistically significant levels in fe-
males (p < 0.001) after the third injection.
However since the elevation of the aforementioned cyto-
kines following a single or repeated injections of MSC-NTF
cells appeared to be minimal and transient, and did not cor-
relate to clinical changes, it may be concluded that these
changes do not indicate a significant biological response.
It is interesting to note that there was no increase in
the key regulators of the humoral immune response, IL-
4 and IL-10, which would be an indication of a Th2 re-
sponse, in any of the treatment groups throughout the
entire study period.IL-4 mediates its function by binding to receptors
expressed on target cells such as T lymphocytes, and
macrophages. In B cells, IL-4 promotes immunological
class switching to IgE and IgG1 isotypes, and upregu-
lates Major Histocompatibility Complex (MHC) Class
II and CD23 expression. It can promote survival,
growth, and differentiation of both T and B lympho-
cytes, mast cells, and endothelial cells. In addition, IL-
4 can inhibit the production of TNF, IL-1, and IL-6 by
macrophages.
In addition, IL-4 promotes alternative activation of
macrophages into M2 cells and inhibits classical acti-
vation of macrophages into M1 cells. An increase in
repair macrophages (M2) is coupled with secretion of
Figure 1 Levels of selected cytokines of male and female C57BL/6 J Mice following single or repeated injections of MSC-NTF cells or
the vehicle control.
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logical inflammation [16]. IL-10 is a pleiotropic cytokine
playing an important role as a regulator of lymphoid and
myeloid cell function. In addition, IL-10 participates in
regulating proliferation and differentiation of B-cells, mast
cells and thymocytes. In parallel, IL-10 inhibits the
production of inflammatory mediators from activated
macrophages and dendritic cells, probably by STAT3
activation [17].
The fact that our treatment did not induce significant
secretion of IL-4 and IL-10 indicates that the repeated
injections did not elicit an immunological or inflamma-
tory reaction.Hematology and biochemistry
No treatment-related changes in mean group hematology
& biochemistry values were noted at 28 days post (last) in-
jection in both the single injection group or in the repeated
injections groups. The relatively comparable values in all
treated groups suggests a lack of dose-dependent changes
and a lack of consistent correlation with other pathological
findings (e.g. histopathological or gross pathological find-
ings), thereby implying an absence of target organ effects.
All of the statistically significant differences reported in
hematology and biochemistry analyses were found to be
within the normal range for the reference values of mice
(Tables 4 and 5).
Table 4 Selected hematology and biochemistry analysis of male C57BL/6 J mice following single or repeated injections
of MSC-NTF cells or the vehicle control
Treatment
4-week study 8-week study 12-week study
Parameter MSC-NTF cells single injection MSC-NTF cells 2 injections MSC-NTF cells 3 injections Vehicle 3 injections
No of animals analyzed 5 5 5 4
White blood cells (×103/μL) 10.4 (1.9) 11.6 (4.0) 12.2* (1.8) 9.9 (0.4)
Red blood cells (×106/μL) 9.82 (0.34) 9.24 (2.6) 9.72 (1.75) 9.27 (0.31)
Hemoglobin (g/dL) 14.8 (0.1) 16.3 (2.0) 15.0 (2.9) 14.5 (0.4)
HCT (%) 50.7 (1.2) 47.1 (14.0) 48.1 (9.2) 47.9 (1.4)
MCV (U3) 51.6 (1.2) 50.8 (1.2) 49.5** (1.1) 51.7 (0.5)
Creatinine (mg/dL) 0.22 (0.02) 0.16 (0.04) 0.17 (0.03) 0.22 (0.05)
Urea (mg/dL) 51.6 (5.3) 46.0 (8.0) 53.0 (11.1) 47.4 (4.1)
Total Protein (g/dL) 5.81 (0.17) 5.75 (0.16) 5.72 (0.2) 5.79 (0.17)
AST (IU/L) 286 (250) 192 (80) 180 (62) 157 (104)
ALT (IU/L) 502 (430) 163 (69) 197 (92) 87 (47)
ALP (IU/L) 124 (14) 89 (7) 87 (3) 95 (25)
Bilirubin (mg/dL) 0.07 (0.02) 0.08 (0.01) 0.08 (0.05) 0.07 (0.01)
Cholesterol (mg/dL) 138 (3) 144 (12) 133 (26) 153 (13)
TRIG (mg/dL) 137 (6) 65 (14) 70 (27) 68 (6)
Phosphorus (mg/dL) 10.6 (0.8) 11.4 (0.7) 10.7 (1.6) 11.2 (0.8)
LDH (IU/L) 1874 (1300) 906 (197) 1000 (464) 735 (331)
Note: Values are mean (SD).
*Indicates statistical significance at p ≤ 0.05.
**Indicates statistical significance at p ≤ 0.01.
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No gross pathological findings related to treatment were
evident at necropsy in any of the animals following the
scheduled termination. Treatment-related histopatho-
logical findings were confined to the injection site of al-
most all MSC-NTF cells’ treated animals. The range and
severity of those findings were mostly of minimal sever-
ity and relatively comparable in all MSC-NTF cells’
treated groups. The most consistent injection site lesions
observed involved multifocal myofiber subchronic in-
flammation and presence of intracellular vacuoles at the
site of inflammation. Neither tumors nor treatment-
related lesions were noted in any of the other evaluated
organs (Figure 2, Table 6).
Discussion
ALS is a complex disease and cannot be explained by the
occurrence of a single event or the disturbance of a single
gene or protein. The disease is likely to be the result of a
multi-step process, ultimately leading to motor neuron de-
generation and clinical symptoms. One of the mechanisms
that have been suggested is the “dying-back” pattern that
might lead to the progressive loss of motor neurons in
ALS [18]. Based on the dying-back hypothesis the muscles
are targeted for therapy in ALS patients.Our preliminary data from a Phase I/II study in ALS pa-
tients using our MSC-NTF cells showed that both IT and
IM injections are safe [14]. These results are in agreement
with several other clinical studies that reported that MSCs
derived from different tissues including bone marrow and
umbilical cord have shown therapeutic potentials in clin-
ical studies without significant adverse events [19-21].
Moreover, IT MSC transplantation and even repeated
intraspinal injection of MSC in ALS patients was found to
be safe [22-24].
Since the autologous MSC and MSC-NTF cells are
propagated ex-vivo before being back-transplanted into
the patient, it is necessary to confirm that repeated MSC-
NTF cells transplantation does not pose any risk to the pa-
tient. The main concern in repeated cell injections is a
possible immune response after the first exposure of the
mouse to human cells. To follow these immune reactions
we used non-immunosuppressed mice and measured the
release of Th1/Th2 cytokines.
Th1/Th2 cytokines (also known as Type-1 and Type-2
cytokines) refer to a pattern of cytokines secreted by two
different subpopulations of CD4+ T-cells that determine
the outcome of an antigenic response toward humoral or
cell-mediated immunity. These cytokines are also secreted
by other cells like such as CD8 (+) T-cells, monocytes,
Table 5 Selected hematology and biochemistry analysis of female C57BL/6 J mice following single or repeated
injections of MSC-NTF cells or the vehicle control
Treatment
4-week study 8-week study 12-week study
Parameter MSC-NTF cells single injection MSC-NTF cells 2 injections MSC-NTF cells 3 injections Vehicle 3 injections
No of animals analyzed 5 5 5 5
White blood cells (×103/μL) 11.1 (2.4) 8.5 (1.9) 9.2 (3.0) 9.0 (1.6)
Red blood cells (×106/μL) 9.74 (0.31) 9.65 (0.41) 8.37* (1.66) 10.97 (0.81)
Hemoglobin (g/dL) 14.7 (0.3) 15.1 (0.5) 12.9* (3.1) 17.0 (1.4)
HCT (%) 49.3 (1.5) 49.4 (2.1) 41.9* (8.1) 55.4 (4.5)
MCV (U3) 50.6 (0.9) 51.2 (0.8) 50.1 (1.1) 50.5 (0.7)
Creatinine (mg/dL) 0.22 (0.0) 0.21 (0.04) 0.22 (0.03) 0.21 (0.04)
Urea (mg/dL) 44.0 (2.3) 33.4 (4.3) 45.1 (4.6) 48.0 (5.2)
Total Protein (g/dL) 5.61 (0.12) 5.94 (0.17) 5.81 (0.35) 5.63 (0.12)
AST (IU/L) 224 (140) 186 (46) 109 (38) 95 (28)
ALT (IU/L) 288 (154) 79 (42) 69 (27) 46 (11)
ALP (IU/L) 161 (7) 146 (9) 117 (24) 124 (17)
Bilirubin (mg/dL) 0.11 (0.03) 0.09 (0.01) 0.07 (0.01) 0.08 (0.01)
Cholesterol (mg/dL) 101 (9) 111 (12) 96 (20) 103 (13)
TRIG (mg/dL) 126 (6) 54 (9) 58 (14) 58 (3)
Phosphorus (mg/dL) 10.4 (0.8) 10.7 (0.9) 10.7 (1.4) 10.8 (1.3)
LDH (IU/L) 921 (450) 784 (163) 693* (142) 461 (86)
Note: Values are mean (SD).
*Indicates statistical significance at p ≤ 0.05.
a b
dc
Figure 2 Sections of the injection site. (a) blood vessel, minimal subchronic inflammation,. H&E × 100, (b) Myofibers - subchronic inflammation,
mild. The arrows indicate the presence of polymorphonuclear cells, mixed with other mononuclear cells (i.e., cells having round nucleus and
abundant eosinophilic cytoplasm, lymphocytes and plasma cells). H&E, X400. (c) Myofibers - subchronic inflammation, minimal. H&E, X100,
(d) Myofibers - subchronic inflammation, minimal. The arrows indicate the presence of intracellular vacuoles. H&E, X400.
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Table 6 Histopathological findings in male and female C57BL/6 J mice following single or repeated injections of MSC-
NTF cells or the vehicle control
Histopathological findings mean severity (Number affected/Total number of animals)
4-week study 8-week study 12-week study









Injection sites – thigh muscles
Blood vessel – inflammation subchronic, focal 0.2 (1/5) 0.0 (5/5) 0.0 (5/5) 0.0 (4/4)
Myofiber subchronic inflammation, multifocal 0.6 (2/5) 1.0 (5/5) 1.0 (5/5) 0.0 (4/4)
Presence of intracellular vacuoles at the site of
inflammation
0.0 (5/5) 0.6 (3/5) 0.8 (4/5) 0.0 (4/4)
Presence of multinucleated giant cells at the site of
inflammation
0.0 (5/5) 0.2 (1/5) 0.2 (1/5) 0.0 (4/4)
Interstitium subchronic inflammation, multifocal 0.2 (1/5) 0.0 (5/5) 0.0 (5/5) 0.0 (4/4)
Interstitium –fibrosis, multifocal 0.2 (1/5) 0.0 (5/5) 0.0 (5/5) 0.0 (4/4)
Females
Injection sites – thigh muscles
Myofiber subchronic inflammation, multifocal 1/0 (5/5) 1.0 (5/5) 1.0 (5/5) 0.0 (5/5)
Presence of intracellular vacuoles at the site of
inflammation
0.8 (4/5) 0.2 (1/5) 0.8 (4/5) 0.0 (5/5)
Presence of multinucleated giant cells at the site of
inflammation
0.2 (1/5) 0.2 (1/5) 0.4 (2/5) 0.0 (5/5)
Granuloma-foreign body, focal 0.4 (2/5) 0.0 (5/5) 0.0 (5/5) 0.0 (5/5)
Gothelf et al. Clinical and Translational Medicine 2014, 3:21 Page 9 of 11
http://www.clintransmed.com/content/3/1/21natural killer cells and B-cells [25]. We measured the pro-
file of Type-1 cytokines including IL-2, IFN-γ, IL-12 and
TNF- α, and Type-2 cytokines including IL-4, IL-5, IL-6,
IL-10 and IL-13, following a single or repeated injections
of MSC-NTF cells. We found transient elevation in IL-5
and IL-6 and to a lower extent IL-2 were elevated after the
first cell injection however comparable changes were ob-
served after repeated injections. The other cytokines
showed very low or undetectable response.
It is interesting to note that the key regulators of the
humoral immune response IL-4 and IL-10 were undetect-
able before or after the injections.
IL-4 mediates its function by binding to receptors
expressed on target cells such as T lymphocytes, and mac-
rophages. On B cells, IL-4 promotes immunological class
switching to IgE and IgG1 isotypes and upregulates Major
Histocompatibility Complex (MHC) class II and CD23 ex-
pression. It can promote survival, growth, and differen-
tiation of both T and B lymphocytes, mast cells, and
endothelial cells. In addition, IL-4 can inhibit the produc-
tion of TNF, IL-1, and IL-6 by macrophages. IL-10 is a
pleiotropic cytokine playing an important role as a regu-
lator of lymphoid and myeloid cell function. In addition,
IL-10 participates in regulating proliferation and differen-
tiation of B-cells, mast cells and thymocytes. The fact that
our treatment didn’t induce significant secretion of IL-4
and IL-10, key regulators in adaptive immunity, indicatesthat the repeated injections do not elicit an immunological
reaction.
Histopathological evaluation revealed neither tumors
nor pathological findings in any major organ. Though a
treatment-related local effect was noted, the repeated in-
jections were not associated with increased severity of
the lesions or any systemic adverse effect. This finding
supports the safety of repeated treatments with MSC-
NTF.
In a similar study, using human umbilical cord mesen-
chymal stem cells in cynomolgus monkeys with repeated
intravenous injection once every 2 weeks, for 6 weeks, it
was demonstrated that no stem cells transplantation-
related toxicity was found [26]. Furthermore we have re-
cently shown that repeated MSC-NTF injections in an
ALS patient treated on a compassionate basis were safe
and well tolerated [27].
In the current study we did not follow the survival and
distribution of the transplanted cells. However, in our pre-
vious experiments we used PKH-26 and feridex (iron nano-
particles) to follow the MSC-NTF cells after intrastriatal
transplantation in rats. We found that only a small percent-
age of the pre-labeled cells migrated and survived. Never-
theless, the procedure was found to be efficient in showing
neuroprotection in models of Parkinson and Huntington
diseases [2,3]. As we reported, six weeks after intrastriatal
transplantation, about one third of the cells were attracted
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larly, in another study we detected small amounts of trans-
planted MSC-NTF cells in the transplanted muscles, after
sciatic nerve injury [5]. Further studies will be needed to
determine whether MSC-NTF can survive in muscle tissue
for an extended period of time.
Conclusions
Based on the results of this study, we conclude that cryo-
preserved MSC-NTF cells known as NurOwn™, when
injected by either one, two or three repeated IM injections
interspaced by four weeks in male and female C57BL/6 J
mice, did not generate any significant systemic toxic ef-
fects. Histopathological evaluation supports this conclu-
sion and points exclusively to a local effect of minimal
severity in the injected muscles.
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